Andrea Cocco
Cagliari, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study.
Journal: American journal of therapeutics
Published: July 23, 2026
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Journal: Journal of clinical medicine
Published: August 27, 2025
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Journal: Expert opinion on biological therapy
Published: January 22, 2024
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Journal: Expert opinion on pharmacotherapy
Published: June 26, 2023
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Journal: Expert opinion on biological therapy
Published: February 27, 2023
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
Journal: Journal of gastrointestinal and liver diseases : JGLD
Published: September 08, 2022
Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular disease.
Journal: Minerva gastroenterology
Published: March 09, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Journal: Inflammatory bowel diseases
Published: January 24, 2022
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Journal: Expert opinion on biological therapy
Published: December 14, 2021
A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: August 27, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026